Edwards Lifesciences (BSP:E1WL34) Debt-to-Equity

: 0.10 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

Edwards Lifesciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was R$122 Mil. Edwards Lifesciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was R$3,283 Mil. Edwards Lifesciences's Total Stockholders Equity for the quarter that ended in Dec. 2023 was R$32,584 Mil. Edwards Lifesciences's debt to equity for the quarter that ended in Dec. 2023 was 0.10.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Edwards Lifesciences's Debt-to-Equity or its related term are showing as below:

BSP:E1WL34' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.1 Med: 0.18 Max: 0.35
Current: 0.1

During the past 13 years, the highest Debt-to-Equity Ratio of Edwards Lifesciences was 0.35. The lowest was 0.10. And the median was 0.18.

BSP:E1WL34's Debt-to-Equity is ranked better than
67.04% of 713 companies
in the Medical Devices & Instruments industry
Industry Median: 0.21 vs BSP:E1WL34: 0.10

Edwards Lifesciences Debt-to-Equity Historical Data

The historical data trend for Edwards Lifesciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Edwards Lifesciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.16

0.15

0.12

0.10

Edwards Lifesciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity																0.12	0.12	0.11	0.10	0.10

Competitive Comparison

For the Medical Devices subindustry, Edwards Lifesciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Edwards Lifesciences Debt-to-Equity Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Edwards Lifesciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Edwards Lifesciences's Debt-to-Equity falls into.

Edwards Lifesciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Edwards Lifesciences's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(122.005	+	3282.866)	/	32583.67
	=	0.10

Edwards Lifesciences's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(122.005	+	3282.866)	/	32583.67
	=	0.10

Edwards Lifesciences (BSP:E1WL34) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Edwards Lifesciences Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Edwards Lifesciences's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Edwards Lifesciences (BSP:E1WL34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Edwards Lifesciences Corp (BSP:E1WL34) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

EW:USA EW:Mexico 1EW:Italy EWL:Germany EWLS:Austria

Address

One Edwards Way, Irvine, CA, USA, 92614

Website

https://www.edwards.com

Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, catheters, and monitoring systems used to measure a patient's heart function during surgery. The firm derives about 55% of its total sales from outside the U.S.

Edwards Lifesciences (BSP:E1WL34) Headlines

No Headlines